MET Alterations are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer

BACKGROUND: Most ALK-positive lung cancers will develop ALK-independent resistance after treatment with next-generation ALK inhibitors. MET amplification has been described in patients progressing on ALK inhibitors, but frequency of this event has not been comprehensively assessed. METHODS: We perfo...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Cancer Res
Egile Nagusiak: Dagogo-Jack, Ibiayi, Yoda, Satoshi, Lennerz, Jochen K., Langenbucher, Adam, Lin, Jessica J., Rooney, Marguerite, Prutisto-Chang, Kylie, Oh, Audris, Adams, Nathaniel A., Yeap, Beow Y., Chin, Emily, Do, Andrew, Marble, Hetal D., Stevens, Sara E., Digumarthy, Subba R., Saxena, Ashish, Nagy, Rebecca J., Benes, Cyril H., Azzoli, Christopher G., Lawrence, Michael, Gainor, Justin F., Shaw, Alice T., Hata, Aaron N.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2020
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7269872/
https://ncbi.nlm.nih.gov/pubmed/32086345
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-3906
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak